A Phase II study of olaparib in breast cancer patients: biological evaluation from a ‘window of opportunity’ trial

Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and “BRCAness” Mutations

(2016) Sanghee Hong et al.   Journal of Oncology Practice

Advances in PARP inhibitors for the treatment of breast cancer

(2015) Omer Dizdar et al.   EXPERT OPINION ON PHARMACOTHERAPY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy

(2014) M I Koukourakis et al.   BRITISH JOURNAL OF CANCER

Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes

(2013) Enilze Ribeiro et al.   PLoS One

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Basal-like subtype and BRCA1 dysfunction in breast cancers

(2008) Yasuo Miyoshi et al.   International Journal of Clinical Oncology